書籍情報から探す
Primary Androgen-Depletion Therapy Prevails Not Only for Metastatic but Also for Nonmetastatic Hormone-Naive Prostate Cancer in Japan - Recent Trends and Efficacy
Mizuki Onozawa*1, Shiro Hinotsu*2, Atsushi Saito*3, Satoshi Uno*4, Hideyuki Akaza*5
*1Dept. of Urology, International University of Health and Welfare Narita Hospital, *2Dept. of Biostatistics, Sapporo Medical University, *3Medical Science, Medical Affairs Japan, Astellas Pharma Inc., *4Data Science, Development, Astellas Pharma Inc., *5Dept. of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies / Graduate School of Interdisciplinary Information Studies, The University of Tokyo
癌と化学療法 48 (7) 911-919, 2021.
*1Dept. of Urology, International University of Health and Welfare Narita Hospital, *2Dept. of Biostatistics, Sapporo Medical University, *3Medical Science, Medical Affairs Japan, Astellas Pharma Inc., *4Data Science, Development, Astellas Pharma Inc., *5Dept. of Strategic Investigation on Comprehensive Cancer Network, Interfaculty Initiative in Information Studies / Graduate School of Interdisciplinary Information Studies, The University of Tokyo
癌と化学療法 48 (7) 911-919, 2021.
- アブストラクト: 従量制は110円(税込)、基本料金制は基本料金に含まれます。
- 全文ダウンロード: 従量制、基本料金制の方共に913円(税込) です。
Use of Ibrutinib in 10 Patients with Treatment-Naive or Relapsed / Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma in Real-World Clinical Practice - A Report from a Single Medical Institution
Yasunobu Sekiguchi*1, Hiroko Iizuka*1, Haruko Takizawa*1, Toru Mitsumori*1, Shigeki Tomita*2, Hiroshi Izumi*2, Mitsuo Okubo*3, Kazunori Miyake*4, Toshiya Osawa*4, Tomohiro Sawada*4, Seiichirou Yoshikawa*5, Masaaki Noguchi*1
*1Dept. of Hematology, *2Dept. of Pathology, *3Dept. of Blood Transfusion, *4Dept. of Clinical Laboratory Medicine, and *5Cancer Treatment Center, Juntendo University Urayasu Hospital
癌と化学療法 48 (7) 921-926, 2021.
*1Dept. of Hematology, *2Dept. of Pathology, *3Dept. of Blood Transfusion, *4Dept. of Clinical Laboratory Medicine, and *5Cancer Treatment Center, Juntendo University Urayasu Hospital
癌と化学療法 48 (7) 921-926, 2021.
- アブストラクト: 従量制は110円(税込)、基本料金制は基本料金に含まれます。
- 全文ダウンロード: 従量制、基本料金制の方共に913円(税込) です。
術前化学療法後に軟骨化生が顕在化した化学療法抵抗性の乳癌の1例